Childhood cancers: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 98
• TP53 8
• PD-1 24
• MYCN 0
• ALK 13
• CD22 30
• BRAF 12
• NF1 12
• ABL1 2
• HER2 25
• PI3K 5
• AKT 1
• CDK4/6 7
• PD-L1 13
• NTRK 10
• NMDA 0
• B7-H3 15
• mTOR 2
• RB1 1
• KMT2A 12
• PSMA 20
• MEK 7
• FLT3 6
• MAPK 5
• CD30 8
• RUNX1 3
• VEGF 5
• IDH 6
• MYC 1
• RET 4
• CD20 12
• ERK 0
• PTEN 2
• CD123 10
• NPM1 9
• EGFR 2
• CTNNB1 2
• FGFR 3
• STAT3 0
• BRCA1 1
• BCL-2 2
• KIT 3
• ROS1 9
• CD33 7
• NRF2 0
• PARP 6
• PPAR 0
• YAP 0
• RAS 1
• CD38 5
• EZH2 0
• JAK 4
• JNK 0
• SNCA 0
• BRCA2 2
• CTLA-4 4
• KRAS 3
• MET 4
• NRAS 0
• VHL 5

4 of 4+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

No running funded project names this disease yet.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors

  NCT02354547· SynerGene Therapeutics, Inc.· Updated 8 May 2026

  “slow recruitment”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress

  NCT04541654· Dana-Farber Cancer Institute· Source

• International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

  NCT02066220· Universitätsklinikum Hamburg-Eppendorf· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 38
• Organoids 15
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 15
• Gene Expression Profiling 125
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 22
• Exome Sequencing 31
• Proteomics 52
• Metabolomics 25
• Mass Spectrometry 13
• Flow Cytometry 87
• Immunohistochemistry 197
• Liquid Biopsy 25
• Circulating Tumor DNA 15
• Xenograft Model Antitumor Assays 134
• Positron-Emission Tomography 52
• Magnetic Resonance Imaging 522
• Machine Learning 69
• Deep Learning 25
• Cohort Studies 328
• Genome-Wide Association Study 22

• Chemotherapy-Mediated Purging Before Testicular Organoid Generation Significantly Reduces Cancer Cells While Not Significantly Reducing Germ Cells.

  Int J Mol Sci, Sept 2026

• Organoids as brain tumour models: bridging the translational gap.

  Dis Model Mech, Sept 2026

• Modeling medulloblastoma pathogenesis and treatment in human cerebellar organoids.

  Genes Dev, Jun 2026

• Enterovirus D68 B3 clade strains are efficiently recovered from cDNA infectious clones in 293T cells and infect human spinal cord organoids.

  J Virol, Apr 2026

• Elucidating Tumorigenesis Mechanisms and Assessing Immunotherapeutic Efficacy in Patient-Derived Medulloblastoma Organoid Models.

  Int J Biol Sci, Apr 2026

• Patient-derived pediatric brain tumor orthotopic xenografts and tumor organoids faithfully recapitulate primary tumors.

  Sci Adv, Apr 2026

• Modeling pediatric low-grade glioma heterogeneity using human forebrain organoids.

  Mol Cancer, Apr 2026

• Patient-derived ependymoma and medulloblastoma tumoroids: generation, biobanking and drug screening.

  Nat Protoc, Mar 2026

• Retinoblastoma: unveiling molecular pathogenesis and pioneering organoid-driven therapeutic innovations.

  Stem Cell Res Ther, Mar 2026

• Patient-derived complex organoids are a critical tool to understand and explore pediatric malignant brain tumors.

  Cancer Metastasis Rev, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.